C
Christopher R. Brown
Researcher at Alnylam Pharmaceuticals
Publications - 44
Citations - 2470
Christopher R. Brown is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Small interfering RNA & RNA. The author has an hindex of 21, co-authored 37 publications receiving 2038 citations. Previous affiliations of Christopher R. Brown include University of California & University of California, Santa Cruz.
Papers
More filters
Journal ArticleDOI
Genome-wide localization of the nuclear transport machinery couples transcriptional status and nuclear organization.
Jason M. Casolari,Christopher R. Brown,Suzanne Komili,Jason A. West,Haley Hieronymus,Pamela A. Silver +5 more
TL;DR: It is shown that transcriptional activation of the GAL genes results in their association with nuclear pore proteins, relocation to the nuclear periphery, and loss of RanGEF association, which indicates that the organization of the genome is coupled via transcriptional state to thenuclear transport machinery.
Journal ArticleDOI
Developmentally induced changes in transcriptional program alter spatial organization across chromosomes
TL;DR: Examination of changes in nuclear organization that accompany stimulus by the mating pheromone alpha factor found that most alpha-factor-induced genes become associated with components of the nuclear envelope and the myosin-like protein Mlp1, which has been implicated in mRNA export, was further shown to exhibit RNA dependence in its association with alpha-Factor- induced genes.
Journal ArticleDOI
Global histone acetylation induces functional genomic reorganization at mammalian nuclear pore complexes
TL;DR: It is shown that inhibiting HDACs leads to significant changes in genomic organization, recruiting regions of transcriptional regulation to mammalian nuclear pore complexes, including the recruitment of promoter regions, euchromatin-rich domains, and differentially expressed genes.
Journal ArticleDOI
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Donald Foster,Christopher R. Brown,Sarfraz Shaikh,Casey Trapp,Mark K Schlegel,Kun Qian,Alfica Sehgal,Kallanthottathil G. Rajeev,Vasant Jadhav,Muthiah Manoharan,Satya Kuchimanchi,Martin Maier,Stuart Milstein +12 more
TL;DR: Liver exposure data indicate that the improvement in potency is predominantly due to increased metabolic stability of the siRNA conjugates, and this work employed an iterative screening approach across multiple siRNAs to arrive at advanced designs with low 2′-deoxy-2′-fluoro content that yield significantly improved potency and duration in preclinical species, including non-human primate.
Journal ArticleDOI
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.
Jayaprakash K. Nair,Husain Attarwala,Alfica Sehgal,Qianfan Wang,Krishna Aluri,Xuemei Zhang,Minggeng Gao,Ju Liu,Ramesh Indrakanti,Sally Schofield,Philip Kretschmer,Christopher R. Brown,Swati Gupta,Jennifer L. S. Willoughby,Julie A. Boshar,Vasant Jadhav,Klaus Charisse,Tracy Zimmermann,Kevin Fitzgerald,Muthiah Manoharan,Kallanthottathil G. Rajeev,Akin Akinc,Renta Hutabarat,Martin Maier +23 more
TL;DR: Compared two siRNAs of the same sequence but with different modification pattern resulting in different degrees of protection against nuclease activity enhanced stability translated into substantially improved liver exposure, gene silencing efficacy and duration of effect in mice.